Intravenous Immunoglobulin (IVIg) for the Treatment of Stiff-Man Syndrome (SMS)
Muscle Rigidity, Spasm, Stiff Man Syndrome
About this trial
This is an interventional treatment trial for Muscle Rigidity focused on measuring Immunotherapy, Muscle Stiffness, Rigidity, Anti-GAD Antibodies, Episodic Spasms, Intravenous High-Dose Immunoglobulin, Stiff-man Syndrome
Eligibility Criteria
Men and non-pregnant women, between 18-75 years of age, who meet a defined criteria for the diagnosis of Stiff-man syndrome (SMS) will be screened as inpatients or in the outpatient clinic. If the diagnosis is confirmed, the patients will be enrolled into the protocol, provided their disease remains symptomatic and poorly responsive to benzodiazepines. Only patients with anti-GAD antibodies will be included. Patients who have not received IVIg in the past 6 months may be included. No pregnant or nursing women (confirmed by a pregnancy screening test). No critically ill patients, such as those with severe cardiomyopathy, and respiratory insufficiency and severely incapacitated patients that require help for self care. No patients with severe renal or hepatic disease, COPD or severe coronary artery disease. No patients with serum IgA level less than 11 mg/dl.
Sites / Locations
- National Institute of Neurological Disorders and Stroke (NINDS)